188 related articles for article (PubMed ID: 34737422)
41. Prognostic value of chromosomal imbalances, gene mutations, and BAP1 expression in uveal melanoma.
Patrone S; Maric I; Rutigliani M; Lanza F; Puntoni M; Banelli B; Rancati S; Angelini G; Amaro A; Ligorio P; Defferrari C; Castagnetta M; Bandelloni R; Mosci C; DeCensi A; Romani M; Pfeffer U; Viaggi S; Coviello DA
Genes Chromosomes Cancer; 2018 Aug; 57(8):387-400. PubMed ID: 29689622
[TBL] [Abstract][Full Text] [Related]
42. Chromosome 3 status combined with BAP1 and EIF1AX mutation profiles are associated with metastasis in uveal melanoma.
Ewens KG; Kanetsky PA; Richards-Yutz J; Purrazzella J; Shields CL; Ganguly T; Ganguly A
Invest Ophthalmol Vis Sci; 2014 Jun; 55(8):5160-7. PubMed ID: 24970262
[TBL] [Abstract][Full Text] [Related]
43. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P
Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076
[TBL] [Abstract][Full Text] [Related]
44. Functional assay for assessment of pathogenicity of BAP1 variants.
Repo PE; Backlund MP; Kivelä TT; Turunen JA
Hum Mol Genet; 2024 Feb; 33(5):426-434. PubMed ID: 37956408
[TBL] [Abstract][Full Text] [Related]
45. Multi-omics Profiling Shows BAP1 Loss Is Associated with Upregulated Cell Adhesion Molecules in Uveal Melanoma.
Baqai U; Purwin TJ; Bechtel N; Chua V; Han A; Hartsough EJ; Kuznetsoff JN; Harbour JW; Aplin AE
Mol Cancer Res; 2022 Aug; 20(8):1260-1271. PubMed ID: 35426938
[TBL] [Abstract][Full Text] [Related]
46. ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer.
Szczepanski AP; Zhao Z; Sosnowski T; Goo YA; Bartom ET; Wang L
Genome Med; 2020 Jul; 12(1):63. PubMed ID: 32669118
[TBL] [Abstract][Full Text] [Related]
47. Clear Cell Renal Cell Carcinoma Subtypes Identified by BAP1 and PBRM1 Expression.
Joseph RW; Kapur P; Serie DJ; Parasramka M; Ho TH; Cheville JC; Frenkel E; Parker AS; Brugarolas J
J Urol; 2016 Jan; 195(1):180-7. PubMed ID: 26300218
[TBL] [Abstract][Full Text] [Related]
48. Basal cell carcinomas developing independently from BAP1-tumor predisposition syndrome in a patient with bilateral uveal melanoma: Diagnostic challenges to identify patients with BAP1-TPDS.
Melzer C; Sharma A; Peters S; Aretz S; Biswas A; Holz FG; Loeffler KU; Herwig-Carl MC
Genes Chromosomes Cancer; 2019 Jun; 58(6):357-364. PubMed ID: 30578689
[TBL] [Abstract][Full Text] [Related]
49. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.
Landreville S; Agapova OA; Matatall KA; Kneass ZT; Onken MD; Lee RS; Bowcock AM; Harbour JW
Clin Cancer Res; 2012 Jan; 18(2):408-16. PubMed ID: 22038994
[TBL] [Abstract][Full Text] [Related]
50. Loss of BAP1 Results in Growth Inhibition and Enhances Mesenchymal-Epithelial Transition in Kidney Tumor Cells.
Chen P; Wang H; Zhang W; Chen Y; Lv Y; Wu D; Guo M; Deng H
Mol Cell Proteomics; 2019 Jul; 18(7):1320-1329. PubMed ID: 30992312
[TBL] [Abstract][Full Text] [Related]
51. Functional Link between BRCA1 and BAP1 through Histone H2A, Heterochromatin and DNA Damage Response.
Fukuda T; Tsuruga T; Kuroda T; Nishikawa H; Ohta T
Curr Cancer Drug Targets; 2016; 16(2):101-9. PubMed ID: 26517537
[TBL] [Abstract][Full Text] [Related]
52. A BAP1 mutation in a Danish family predisposes to uveal melanoma and other cancers.
Aoude LG; Wadt K; Bojesen A; Crüger D; Borg A; Trent JM; Brown KM; Gerdes AM; Jönsson G; Hayward NK
PLoS One; 2013; 8(8):e72144. PubMed ID: 23977234
[TBL] [Abstract][Full Text] [Related]
53. BAP1 Loss Is Associated with DNA Methylomic Repatterning in Highly Aggressive Class 2 Uveal Melanomas.
Field MG; Kuznetsov JN; Bussies PL; Cai LZ; Alawa KA; Decatur CL; Kurtenbach S; Harbour JW
Clin Cancer Res; 2019 Sep; 25(18):5663-5673. PubMed ID: 31285370
[TBL] [Abstract][Full Text] [Related]
54. Genotypic and Phenotypic Features of BAP1 Cancer Syndrome: A Report of 8 New Families and Review of Cases in the Literature.
Haugh AM; Njauw CN; Bubley JA; Verzì AE; Zhang B; Kudalkar E; VandenBoom T; Walton K; Swick BL; Kumar R; Rana HQ; Cochrane S; McCormick SR; Shea CR; Tsao H; Gerami P
JAMA Dermatol; 2017 Oct; 153(10):999-1006. PubMed ID: 28793149
[TBL] [Abstract][Full Text] [Related]
55. Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma.
Koopmans AE; Verdijk RM; Brouwer RW; van den Bosch TP; van den Berg MM; Vaarwater J; Kockx CE; Paridaens D; Naus NC; Nellist M; van IJcken WF; Kiliç E; de Klein A
Mod Pathol; 2014 Oct; 27(10):1321-30. PubMed ID: 24633195
[TBL] [Abstract][Full Text] [Related]
56. Therapeutic targeting of BAP1/ASXL3 sub-complex in ASCL1-dependent small cell lung cancer.
Tsuboyama N; Wang R; Szczepanski AP; Chen H; Zhao Z; Shi L; Wang L
Oncogene; 2022 Apr; 41(15):2152-2162. PubMed ID: 35194152
[TBL] [Abstract][Full Text] [Related]
57. Germline BAP1 mutations predispose to malignant mesothelioma.
Testa JR; Cheung M; Pei J; Below JE; Tan Y; Sementino E; Cox NJ; Dogan AU; Pass HI; Trusa S; Hesdorffer M; Nasu M; Powers A; Rivera Z; Comertpay S; Tanji M; Gaudino G; Yang H; Carbone M
Nat Genet; 2011 Aug; 43(10):1022-5. PubMed ID: 21874000
[TBL] [Abstract][Full Text] [Related]
58. PTEN loss confers sensitivity to rapalogs in clear cell renal cell carcinoma.
Liu XL; Zhang GM; Huang SS; Shi WH; Ye LX; Ren ZL; Zhang JJ; Liu SW; Yu L; Li YL
Acta Pharmacol Sin; 2022 Sep; 43(9):2397-2409. PubMed ID: 35165399
[TBL] [Abstract][Full Text] [Related]
59. Uveal Melanoma Nuclear BRCA1-Associated Protein-1 Immunoreactivity Is an Indicator of Metastasis.
Szalai E; Wells JR; Ward L; Grossniklaus HE
Ophthalmology; 2018 Feb; 125(2):203-209. PubMed ID: 28823399
[TBL] [Abstract][Full Text] [Related]
60. BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations.
Piris A; Mihm MC; Hoang MP
Hum Pathol; 2015 Feb; 46(2):239-45. PubMed ID: 25479927
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
